Table 1

Clinicodemographic characteristics at baseline

Baseline characteristicsRCC (n=58)UC (n=48)Overall (n=106)
N (%)N (%)N (%)
Age
 Median, years (range)66 (25–82)72 (47–87)68(25-87)
Gender
 Male40 (69)35 (73)75 (71)
 Female18 (31)13 (27)31 (29)
Histology
 ccRCC46 (79)NANA
 nccRCC12 (21)NANA
 UC*NA47 (98)NA
 Non-UC†NA1 (2)NA
ECOG performance status
 021 (36)12 (25)33 (31)
 129 (50)28 (58)57 (54)
 2–38 (14)8 (17)16 (15)
RCC IMDC risk group17
 Favorable10 (17)NANA
 Intermediate39 (67)NANA
 Poor9 (16)NANA
UC risk group
Platinum-sensitive group: Bajorin criteria19 n=21
 0NA5 (24)NA
 1NA13 (62)NA
 2NA3 (14)NA
UC risk group
Platinum-refractory group: Bellmunt criteria18 n=33
 0NA2 (6)NA
 1NA8 (24)NA
 2NA19 (58)NA
 3NA4 (12)NA
Number of prior systemic therapies
 020 (34)22 (46)42 (40)
 126 (45)24 (50)50 (47)
 24 (7)2 (4)6 (6)
 ≥38 (14)0 (0)8 (8)
Type of CPI regimen
 PD-1/PD-L1 inhibitor monotherapy38 (66)47 (98)85 (80)
 PD-1/PD-L1 +CTLA-4 inhibitor9 (16)1 (2)10 (9)
 PD-1/PD-L1 +VEGF inhibitor11 (19)0 (0)11 (10)
Sites of metastases‡
 Lymph nodes46 (79)43 (90)89 (84)
 Lung42 (72)24 (50)66 (62)
 Bone16 (28)8 (17)24 (23)
 Liver12 (21)14 (29)26 (25)
 Brain5 (9)0 (0)5 (5)
  • *Includes pure urothelial histology and mixed histology with predominant urothelial component.

  • †Includes one patient with a small cell bladder tumor.

  • ‡Patients may have had more than one metastatic site.

  • ccRCC, clear cell renal cell carcinoma; CPI, checkpoint inhibitors; CTLA-4, cytotoxic T lymphocyte associated protein-4; ECOG, Eastern Cooperative Oncology Group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; NA, not applicable; nccRCC, non-clear cell renal cell carcinoma; PD-1, programmed death-1; PD-L1, programmed death ligand-1; RCC, renal cell carcinoma; UC, urothelial carcinoma; VEGF, vascular endothelial growth factor.